Pfizer Corporation

National Institutes of Health, a Component of the US Dept. of Health & Human Services

The Brigham and Women's Hospital, Inc.

Leland Stanford Junior University

Bolt Biotherapeutics, Inc.

Other

University of Houston System

Arthur Lee

Christoph Martin Dehnhardt

Joseph Walter Strohbach

Eddine Saiah

David Hepworth

Christoph Wolfgang Zapf

Nikolaos Papaioannou

Stephen Wayne Wright

Frank Eldridge Lovering

Katherine Lin Lee

John David Trzupek

Seungil Han

Lori Krim Gavrin

John Paul Mathias

Akshay Patny

Kevin Joseph Curran

Xiaolun Wang

Joel A Goldberg

Michael Dennis Lowe

Richard Vargas

David R Anderson

Mark Edward Bunnage

Horng-Chih Huang

Paul B Yu

Betsy Susan Pierce

Edgar George Engleman

David Y Jackson

Asaf Alimardanov

Shelley Erin Ackerman

Michael Nathaniel Alonso

Gregory D Cuny

Wei Ping Zheng

John C McKew

Xiuli Huang

Philip Edward Sanderson

Justin A Kenkel

Agustin H Mohedas

Wenwei Huang

Dafydd Rhys Owen

Min Shen

Khalida Shamim

Jian-kang Jiang

Gregory J Tawa

Junfeng Huang

Christophe Philippe Allais

Duk Hi Lee

Gurmit Singh Grewal

Xin Xu

Paresma R Patel

David Randolph Anderson

Joel Adam Goldberg

Richard P Laura

Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. In an embodiment, a pharmaceutical composition can be in a liquid dosage form and can comprise a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof as an adjuvant and a therapeutic agent. In another embodiment, a method of adjuvant treating a disorder or condition can comprising administering the pharmaceutical composition to a patient.

Bicyclic-fused heteroaryl or aryl compounds

Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to treat subjects with Sj&#xf6;gren's syndrome, or diffuse intrinsic pontine glioma (DIPG).

ALK2 inhibitors and methods for inhibiting BMP signaling

The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via the linker. Methods for treating cancer with the immunoconjugates of the invention are also described.

Antibody adjuvant conjugates

The invention provides an immunoconjugate of formula: or pharmaceutically acceptable salt thereof, wherein subscript r is an integer from 1 to 10, subscript n is an integer from about 2 to about 25, and 'Ab' is an antibody construct that has an antigen binding domain that binds HER2. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.

Immunoconjugates targeting HER2

Trisubstituted triazines having the formula: 

Triazine compounds, compositions, and methods

Anti-oxidant compounds and compositions

The present invention provides bicyclic heteroaryl inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. Exemplary compounds include those of Formula I:  These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.

Compositions and methods for inhibiting BMP

Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators

Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed. 

Growing community of inventors

San Carlos, CA, United States of America

Arthur Lee